Fosamax for Paget's Disease: Off-Label Evidence, Risks, and Clinical Tradeoffs

What Is Paget's Disease and Why Does It Need Treatment?

Paget's disease of bone (PDB) is a chronic skeletal disorder characterized by focal areas of excessive bone remodeling, producing structurally disorganized and mechanically weak bone. The condition affects an estimated 1-3% of adults over age 55 in the United States and Europe, though prevalence varies sharply by geography and ethnicity 1. Most patients are asymptomatic at diagnosis.

When symptoms do occur, they include bone pain, skeletal deformity, pathologic fractures, and secondary osteoarthritis of adjacent joints. Neurological complications can develop when pagetic bone encroaches on neural structures. Hearing loss occurs in up to 37% of patients with skull involvement 2. The biochemical hallmark is an elevated serum total alkaline phosphatase (ALP), which reflects the rate of osteoblastic bone formation coupled to excessive osteoclastic resorption 3.

The primary pharmacologic goal is suppressing the accelerated bone turnover. Bisphosphonates are the treatment class of choice. They bind to hydroxyapatite in bone and inhibit osteoclast function by disrupting the mevalonate pathway 4. The Endocrine Society's 2014 clinical practice guideline recommends treating symptomatic patients and those at risk for future complications, with zoledronic acid as the preferred agent and oral bisphosphonates (including alendronate) as alternatives 5.

FDA-Approved Status of Alendronate for Paget's Disease

Alendronate holds FDA approval for Paget's disease specifically at the 40 mg daily oral dose taken for six months. This approval is separate from its osteoporosis indication. The FDA granted this indication based on two key trials in the mid-1990s showing that 40 mg daily normalized alkaline phosphatase in approximately 48% of patients at 6 months, with an additional 15-20% achieving partial biochemical response 6.

Here is the distinction that matters clinically. The 70 mg once-weekly tablet, which is the formulation most pharmacies stock and most prescribers are familiar with, carries FDA approval only for osteoporosis 7. Prescribing the weekly 70 mg tablet for Paget's disease constitutes off-label use. Some clinicians do this for patient convenience, reasoning that 70 mg weekly delivers a comparable cumulative weekly dose to 40 mg daily (280 mg/week vs. 490 mg/week, respectively). These are not pharmacologically equivalent regimens, and no randomized trial has validated 70 mg weekly for Paget's disease 8.

The 40 mg daily Paget's-specific tablet has become harder to source at some pharmacies, which contributes to off-label prescribing of the weekly formulation. Generic alendronate 40 mg remains available, and GoodRx pricing data places it between $15 and $30 for a 30-day supply 9.

Clinical Evidence: How Effective Is Alendronate for Paget's Disease?

The strongest alendronate-specific data come from two multicenter trials published in the mid-1990s. In a double-blind study of 55 patients with moderate-to-severe Paget's disease, alendronate 40 mg daily for 6 months normalized serum ALP in 48% of patients compared to 0% on placebo 10. A subsequent open-label extension found that biochemical remission persisted for a median of 1.5 years after treatment cessation in responders.

A second trial compared alendronate 40 mg daily to etidronate 400 mg daily (a first-generation bisphosphonate) in 72 patients. Alendronate produced ALP normalization in 63% vs. 17% with etidronate at 6 months, establishing alendronate as clearly superior to earlier oral bisphosphonates 11. Pain scores improved in both groups, but significantly more in the alendronate arm.

These results, while meaningful at the time, have been superseded by the zoledronic acid data. The HORIZON-PDB trial (N=357) randomized patients with active Paget's disease to a single 5 mg IV zoledronic acid infusion versus 60 mg daily oral risedronate for 60 days. Therapeutic response (defined as either ALP normalization or at least 75% reduction in excess ALP) occurred in 96% of zoledronic acid patients versus 74% of risedronate patients at 6 months (P<0.001) 12. Complete biochemical normalization reached 89% with zoledronic acid versus 58% with risedronate.

No head-to-head trial of alendronate versus zoledronic acid exists for Paget's disease. Based on indirect comparison, alendronate's 48-65% normalization rate falls below both zoledronic acid (89%) and risedronate (58%). Dr. Stuart Ralston, who led the PRISM trial and has published extensively on Paget's disease, has stated: "Zoledronic acid has become the treatment of choice for most patients with Paget's disease requiring therapy, given its superior efficacy and single-dose convenience" 13.

When Clinicians Choose Alendronate Over Zoledronic Acid

Despite zoledronic acid's superiority in remission rates, alendronate remains a reasonable second-line option in several clinical scenarios. Renal impairment is the most common reason. Zoledronic acid is contraindicated in patients with creatinine clearance below 35 mL/min due to nephrotoxicity risk, while oral alendronate carries a lower threshold of 35 mL/min in labeling but has been used cautiously at reduced doses in mild-to-moderate renal insufficiency 14.

Patient refusal of IV therapy is another consideration. Some patients, particularly those with needle phobia or limited access to infusion centers, prefer a daily oral tablet. The acute-phase reaction following zoledronic acid infusion, which includes fever, myalgia, and flu-like symptoms in 10-42% of patients within 72 hours of infusion, also drives some patients toward oral options 15.

Cost plays a role in specific insurance environments. A single zoledronic acid infusion, including the drug and facility fee, typically runs $1,200-$2,500 without insurance. Generic oral alendronate for the full 6-month Paget's course costs approximately $90-180 out of pocket 16. For uninsured or underinsured patients, this difference can be decisive.

The American Association of Clinical Endocrinologists (AACE) has acknowledged oral bisphosphonates as acceptable alternatives when IV therapy is not feasible, provided the patient can tolerate the strict dosing requirements (empty stomach, upright position for 30 minutes, no food or other medications for at least 30 minutes after dosing) 17.

Risks and Side Effects of Alendronate in Paget's Disease

The adverse effect profile of alendronate at Paget's doses (40 mg daily) is more pronounced than at osteoporosis doses (10 mg daily or 70 mg weekly) because of the higher daily exposure. Upper gastrointestinal complaints, including dyspepsia, nausea, abdominal pain, and esophageal irritation, affect roughly 10-15% of patients on the 40 mg daily regimen 18. Esophageal ulceration and stricture are rare but documented, particularly in patients who do not follow the upright-dosing protocol.

The FDA added a warning about esophageal cancer risk to all oral bisphosphonate labels in 2011, though a subsequent meta-analysis of case-control studies found no statistically significant association (OR 1.07 to 95% CI 0.77-1.49) 19. Musculoskeletal pain, sometimes severe, has been reported and may persist for weeks to months. The FDA issued a safety communication in 2008 noting that bisphosphonate-associated musculoskeletal pain may be under-recognized 20.

Osteonecrosis of the jaw (ONJ) is a rare complication associated with all bisphosphonates. The estimated incidence with oral bisphosphonates for osteoporosis ranges from 1 in 10,000 to 1 in 100,000 patient-years of exposure, and the risk increases with duration of therapy and concurrent dental procedures 21. Paget's patients may face modestly higher risk due to the higher daily dose and greater skeletal uptake of bisphosphonate in pagetic bone.

Atypical femoral fractures (AFFs) have been associated with long-term bisphosphonate use, typically beyond 3-5 years of continuous therapy. Since the standard Paget's course is only 6 months, AFF risk is low for a single treatment cycle. The risk becomes more relevant if repeated retreatment courses accumulate over years 22. An ASBMR task force report found AFF risk was 3.2 to 100 times higher in bisphosphonate users compared to non-users, with risk increasing by approximately 3% per year of use 23.

Hypocalcemia can occur, especially in patients with high-turnover Paget's disease where bisphosphonate-induced suppression of resorption outpaces calcium release from bone. The Endocrine Society guideline recommends ensuring adequate calcium (1,000-1 to 200 mg/day) and vitamin D (600-800 IU/day minimum) supplementation before and during treatment 5.

Dosing Protocol and Monitoring

The standard protocol for alendronate in Paget's disease is 40 mg orally once daily for 6 months. The tablet must be taken first thing in the morning on an empty stomach with 6-8 ounces of plain water. The patient should not lie down and should avoid eating, drinking anything other than water, or taking other medications for at least 30 minutes 24.

Dr. Ethel Siris of Columbia University, a leading Paget's disease researcher, has noted: "Compliance with the fasting and upright-posture requirements is essential. GI side effects increase markedly when patients take alendronate with food or lie down afterward" 25.

Baseline labs should include serum total ALP, calcium, 25-hydroxyvitamin D, and creatinine. ALP should be rechecked at 3 months to assess early response and again at 6 months at treatment completion. A post-treatment ALP within the normal reference range indicates biochemical remission 5.

After treatment completion, ALP monitoring should continue every 6-12 months. Retreatment is indicated when ALP rises above the midpoint of the normal reference range, when ALP rises by 25% or more above its nadir, or when symptoms recur 26. The median time to biochemical relapse after a single alendronate course is approximately 18-24 months, compared to more than 6 years with zoledronic acid 12.

Comparing Oral Bisphosphonates for Paget's Disease

Three oral bisphosphonates have FDA approval or established evidence for Paget's disease: alendronate 40 mg daily, risedronate 30 mg daily for 60 days, and tiludronate 400 mg daily for 3 months. Etidronate, the original oral bisphosphonate for Paget's, is no longer used because of inferior efficacy and a risk of osteomalacia at therapeutic doses 27.

Risedronate 30 mg daily for 2 months produced ALP normalization in 73% of patients in its key trial, compared to approximately 48-65% with alendronate 28. Risedronate also has the advantage of a shorter treatment course (60 days vs. 180 days). Tiludronate's normalization rate sits lower, at approximately 35% 29.

A Cochrane systematic review of bisphosphonates for Paget's disease concluded that while all bisphosphonates reduced ALP more effectively than placebo or etidronate, "there is insufficient evidence to determine whether reducing and maintaining biochemical markers within the normal range improves patient-centered outcomes such as pain, mobility, or fracture rates" 30. This evidence gap is significant. The PRISM trial (N=1,324) randomized patients to "intensive" bisphosphonate therapy targeting ALP normalization versus "symptomatic" treatment only when pain was present. At a median 3-year follow-up, there was no difference in bone pain, quality of life, or fracture rates between groups 31.

These findings have led some experts to question the routine treatment of asymptomatic Paget's disease. The Endocrine Society guideline continues to recommend treatment for patients at risk of complications, including those with pagetic involvement of weight-bearing bones, skull, or spine, or those facing orthopedic surgery at a pagetic site 5.

Special Populations and Contraindications

Alendronate is contraindicated in patients with esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, hypocalcemia, or creatinine clearance below 35 mL/min 24. It is pregnancy category C and should not be used in premenopausal women of childbearing potential with Paget's disease unless the benefit clearly outweighs the unknown fetal risk, as bisphosphonates cross the placenta and have caused skeletal abnormalities in animal studies 32.

Patients on concurrent corticosteroids may face additional bone-loss risk independent of Paget's, and the combination requires careful monitoring. Concurrent use of NSAIDs increases GI toxicity risk. Calcium supplements, antacids, and other divalent-cation-containing products must be separated from alendronate by at least 30 minutes to avoid chelation and reduced absorption 24.

For patients with active upper GI disease (gastritis, duodenal ulcer, GERD refractory to proton pump inhibitors), IV zoledronic acid is the safer bisphosphonate choice even though it carries its own renal considerations. Denosumab, a RANKL inhibitor, has shown efficacy in case reports and small series for Paget's disease refractory to bisphosphonates, though it lacks FDA approval for this indication 33.

Serum ALP at 6 months after the final dose of a completed alendronate course is the most reliable predictor of durable remission. Patients who achieve full normalization have a longer relapse-free interval than those with partial responses 5.